Form PT	<u></u>	449 Substitute	IIS Departme	ent of Commerce	Application Number	10/037 3/1	
011111	O-1	447 Substitute	_	ademark Office		January 4, 2	002
			ratent and 11	auemaik Office		David Baltime	
VEORN	ЛЛТ	ION DISCLOSU	DE STATEME	OIPE		1636	010
		sheets if necessar		(g)		D. Guzo	
	Jur .	4	,	- 007		75723-	
		86		OCT 7 & 2008 0	Attorney Docket No.	ZA/JPW/GJG/C:	S
A.	OCT 1	4 2008	NON PATENT	LITERATE BOC	UMENTS		
Examiner Initials	No.	Include name of the book, magazine, jour	author (in CAPITA nal, serial, symposiu	L LETTERS), title of th im, catalog, etc.) date, pa d/or country where pub	e article (when appropi age(s), volume-issue nui	riate), title of the item nber(s), publisher, city	T ²
	1	June 18, 200 <i>Pharmaceutic</i>	endant-Appe 8, in the c als, Inc.,	ellant Eli Li concurrent li et al., v. E ne Federal Ci	lly and Compa tigation capt li Lilly and	cioned Ariad	
	2	in the concu <i>Pharmaceutic</i>	rrent litic als, Inc.,	opellees, filogation caption et al., v. E. ne Federal Cir	ned Ariad li Lilly and	Co., U.S.	
	3	Amgen's Moti Calame Relat Pomerantz, i <i>Inc., et al.</i>	on to Precl ing to Expe n the concu v. Ariad P	s Memorandum lude the Opinicriments Condurrent litigate Pharmaceutical District of I	ions of Dr. F acted by Dr. tion captione ls, Inc., et	Kathryn Joel ed <i>Amgen,</i> al., U.S.	
	4	Amgen's Part Experts on W the concurre <i>Ariad Pharma</i>	ial Motion illfulness nt litigati <i>ceuticals,</i>	s Memorandum to Preclude A and Lack of I on captioned Inc., et al., aware, CA No	Ariad's Proff Inequitable (<i>Amgen, Inc.,</i> , U.S. Distri	Tered Conduct, in et al. vct Court	
	5	Amgen's Moti the concurre <i>Ariad Pharma</i>	on for Summ nt litigati <i>ceuticals,</i>	s Memorandum nary Judgment on captioned Inc., et al., aware, CA No.	of Noninfrin Amgen, Inc., U.S. Distri	ngement, in et al. v. ct Court	
	6	Amgen's Moti v. Ravetch, <i>Inc., et al</i> .	on to Precl in the conc <i>v. Ariad E</i>	s Memorandum ude Certain (current litiga Pharmaceutica District of I	Opinions of Dation caption ls, Inc., et	or. Jeffrey led <i>Amgen,</i> al., U.S.	
XAMINER GNATURE	:			DATE CONSIDERED			_

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark here if English language Translation is attached.

Applicants: David Baltimore, et al.

Serial No.: 10/037,341 Filed: January 4, 2002

Exhibit A

					D 4	Tames 4 00	$\overline{}$
			Patent and Trademar	••	<u> </u>	January 4, 20	
						David Baltimo	<u>ore</u>
NFOR	MAT	ION DISCLOSU	JRE STATEMENT			1636	
Use sev	eral s	sheets if necessar	·y)	Exa	miner Name	D. Guzo	
				A ***	orney Docket No.	75723-	
				Atte	orney Docket No.	ZA/JPW/GJG/CS	3
				TUDE DOCUM	ENTE		
E	Cita	Include nome of the	NON PATENT LITERA author (in CAPITAL LETTE)			riata) title of the item	T ²
Examiner Initials*	Cite No.1		rnal, serial, symposium, catalog				•
		(15 5 5 1.4) 1.1.1.1.g. 1.2.1.1.5, j 5 2.		ry where publishe		(-/, L	
		Amgen's Mot	B Defendant's Mem Lon for Summary J	udgment or	n Willfulne	ess, in the	
		Ariad Pharma	litigation captio aceuticals, Inc., crict of Delaware	et al., t	J.S. Distr	ict Court	
	8	Motion for S Description Inc., et al	B Defendant's Bri Summary Judgment in the concurre v. Ariad Pharma art for the Distr	for Lack on the litigate ceuticals,	of Adequate tion caption . Inc., et	e Written oned <i>Amgen,</i> al., U.S.	
	9	Amgen's Mot: Sullivan, in Inc., et al	B Defendant's Memion to Preclude to the concurrent . v. Ariad Pharma	he Testimo litigation ceuticals,	ony of Dr. n captioned , Inc., et	Ryan d <i>Amgen,</i> <i>al.</i> , U.S.	
	10	Construction Inc., et al	B Defendant's Reb n, in the concurr . v. Ariad Pharma urt for the Distr	ent litiga ceuticals,	ation capt: , <i>Inc., et</i>	ioned <i>Amgen,</i> al., U.S.	
	11	to Ariad and for Lack of litigation of Pharmaceutic	Amgen Entities'd the Institution Subject Matter J Captioned Amgen, Cals, Inc., et al Delaware, CA No.	's Motion urisdiction Inc., et a ., U.S. Di	for Partia on, in the al. v. Aria istrict Cou	al Dismissal concurrent ad	
	12	to Ariad and Judgment on litigation of Pharmaceutic	Amgen Entities'd the Institution Inequitable Cond captioned Amgen, cals, Inc., et al Delaware, CA No.	s' Motion luct, in th <i>Inc., et a</i> , U.S. Di	for Partiane concurrent of the concurrent of the concurrent of the concurrent	al Summary ent ad	

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'Applicant is to place a checkmark here if English language Translation is attached.

			40.400= 0.44	
Form PTO-1449 Substitute	U.S. Department of Commerce	Application Number		
	Patent and Trademark Office	Filing Date	January 4, 20	
			David Baltimo	ore
INFORMATION DISCLOS	URE STATEMENT	Art Unit	1636	
(Use several sheets if necessa	ry)	Examiner Name	D. Guzo	
		Attorney Docket No.	75723- ZA/JPW/GJG/CS	5
	NON PATENT LITERATURE DOC	CUMENTS		
	ne author (in CAPITAL LETTERS), title of the urnal, serial, symposium, catalog, etc.) date, p and/or country where pub	age(s), volume-issue nu		T ²
to Ariad an Expert Test 13 Dr. Aaron C captioned A Inc., et al	8 Amgen Entities' Answer de the Institutions' Daub imony of the Honorable Giechanover, in the concument, Inc., et al. v. Ar., U.S. District Court for No. 06-259-MPT;	ert Motion terald J. Mos rrent litiga riad Pharmace	o Preclude singhoff and tion uticals,	
in the cond v. Ariad Ph	8 Amgen's Answering Brie current litigation caption carmaceuticals, Inc., et strict of Delaware, CA No	ned <i>Amgen, I</i> al., U.S. Di	nc., et al. strict Court	
Motion for Jurisdiction Inc., et all	98 Reply Memorandum in Su Partial Dismissal for La on, in the concurrent lit 1. v. Ariad Pharmaceutica ourt for the District of	ck of Subjec igation capt ls, Inc., et	t Matter ioned <i>Amgen,</i> al., U.S.	
Motion for 16 in the cond v. Ariad Ph	08 Reply Memorandum in Su Partial Summary Judgment current litigation caption parmaceuticals, Inc., et strict of Delaware, CA No	on Inequita ned <i>Amgen, I</i> al., U.S. Di	ble Conduct, nc., et al. strict Court	
Motion to F Mossinghoff litigation Pharmaceuts	Reply Memorandum in Sureclude Expert Testimony and Dr. Aaron Ciechanov captioned Amgen, Inc., et al., U.S. Delaware, CA No. 06-259	of Mr. Gera er, in the c et al. v. Ari District Co	ld J. oncurrent <i>ad</i>	
EXAMINER SIGNATURE	DATE CONSIDERED			•

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached.

Form PTO-1449 Substitute U.S. Department of Compartment and Trademark O INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			nd Trademark Office	Filing Date First Named Inventor Art Unit Examiner Name	January 4, 2002 David Baltimore 1636 D. Guzo 75723-	
Examiner Initials*	Cite No.1	NON PA Include name of the author (in C (book, magazine, journal, serial, s		e article (when approp ge(s), volume-issue nu		T ²
	18	June 6, 2008 Amgen Their Motion for S Patent No. 6,410,5 Description Under litigation caption Pharmaceuticals, I District of Delawa	Entities' Reply I ummary Judgment of 16 for Lack of Ade 35 U.S.C. § 112, a ed Amgen, Inc., et nc., et al., U.S.	Brief in Supple Invalidity equate Writte in the concust al. v. Aria	of U.S. en rrent ad	
	19	June 6, 2008 Amgen Entities' Reply Brief in Support of Their Motion for Summary Judgment of Noninfringement of U.S. Patent No. 6,410,516, in the concurrent litigation captioned Amgen, Inc., et al. v. Ariad Pharmaceuticals, Inc., et al., U.S. District Court for the District of Delaware, CA No. 06-259-MPT;				
	20	June 6, 2008 Amgen Their Motion for S the concurrent lit Ariad Pharmaceutic for the District o	ummary Judgment of igation captioned als, Inc., et al.	f Non-willfu Amgen, Inc. , U.S. Distr	lness, in , <i>et al. v.</i> ict Court	
	21	June 6, 2008 Amgen Daubert Motion to Unreliable Opinion Damages, in the colling Inc., et al. v. Ar District Court for MPT;	Preclude Certain Tof Dr. Ryan Sull: ncurrent litigation iad Pharmaceutica	Unsupported a ivan Relating on captioned ls, Inc., et	and g to <i>Amgen,</i> <i>al.</i> , U.S.	
	22	June 6, 2008 Amgen Daubert Motion to Dr. Jeffrey v. Rav Inherent Anticipat captioned Amgen, I Inc., et al., U.S. Delaware, CA No. 0	Preclude Certain letch Relating to Tion, in the concur nc., et al. v. Ar. District Court fo	Proffered Op Written Desc Prent litiga <i>iad Pharmace</i>	inions of ription and tion uticals,	
EXAMINEF SIGNATUR			DATE CONSIDERED			

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark here if English language Translation is attached.

Application Number 10/037,341 Form PTO-1449 Substitute **U.S. Department of Commerce** January 4, 2002 Filing Date **Patent and Trademark Office** First Named Inventor David Baltimore 1636 Art Unit INFORMATION DISCLOSURE STATEMENT D. Guzo Examiner Name (Use several sheets if necessary) 75723-Attorney Docket No. ZA/JPW/GJG/CS NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item Examiner Cite (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city No.1 Initials* and/or country where published. June 6, 2008 Amgen Entities' Reply Brief in Support of Their Daubert Motion to Preclude Certain Inadmissible Opinions of Dr. Kathryn Calame Relating to Experiments 23 Performed by Dr. Joel Pomerantz, in the concurrent litigation captioned Amgen, Inc., et al. v. Ariad Pharmaceuticals, Inc., et al., U.S. District Court for the District of Delaware, CA No. 06-259-MPT; June 6, 2008 Amgen Entities' Reply Brief in Support of Their Motion to Preclude Ariad's Proffered Experts on Willfulness and Inequitable Conduct from Opining on Intent, 24 State of Mind, and Other Matters, in the concurrent litigation captioned Amgen, Inc., et al. v. Ariad Pharmaceuticals, Inc., et al., U.S. District Court for the District of Delaware, CA No. 06-259-MPT; September 19, 2008 Memorandum and Order on Claim Construction, in the concurrent litigation captioned Amgen, 25 Inc., et al. v. Ariad Pharmaceuticals, Inc., et al., U.S. District Court for the District of Delaware, CA No. 06-259-MPT; September 19, 2008 Memorandum and Order on Defendant's Motion for Partial Dismissal for Lack of Subject Matter Jurisdiction and Motion for Summary Judgment on Inequitable 26 Conduct, in the concurrent litigation captioned Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc., et al., U.S. District Court for the District of Delaware, CA No. 06-259-MPT; September 19, 2008 Memorandum and Order on Plaintiff's Motion for Summary Judgment for Noninfringement of U.S. Patent No. 6,410,516, in the concurrent litigation captioned Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc., et al., U.S. District Court for the District of

EXAMINER SIGNATURE

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark here if English language Translation is attached.

Delaware, CA No. 06-259-MPT

Form PTO-1449 Substitute U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			Application Number Filing Date First Named Inventor Art Unit Examiner Name Attorney Docket No.	January 4, 20 David Baltimo 1636 D. Guzo 75723-	ore
Examiner	Cite	NON PATENT LITERATURE DOC Include name of the author (in CAPITAL LETTERS), title of the		-i-ta) title of the item	T ²
Initials*	No.1	(book, magazine, journal, serial, symposium, catalog, etc.) date, pa and/or country where pub	age(s), volume-issue nu		•
	28	September 23, 2008 Defendant's Moti- Judgment Pursuant to Fed. R. Civ. P concurrent litigation captioned <i>Amg</i> <i>Ariad Pharmaceuticals, Inc., et al.</i> for the District of Delaware, CA No	. 54(b), in en, <i>Inc., et</i> , U.S. Distr	the <i>al. v.</i> ict Court	
	29	September 25, 2008 Plaintiff's Memore Defendant's Motion to Dismiss or for Fed. R. Civ. P. 54(b), in the concurationed Amgen, Inc., et al. v. Ar Inc., et al., U.S. District Court for Delaware, CA No. 06-259-MPT;	r Judgment P rrent litiga <i>iad Pharmace</i>	ursuant to tion uticals,	
	30	September 26, 2008 Defendant's Replosition of Their Motion to Dismiss or for J. R. Civ. P. 54(b), in the concurrent Amgen, Inc., et al. v. Ariad Pharma U.S. District Court for the Distric 06-259-MPT;	udgment Purs litigation ceuticals, I	uant to Fed. captioned nc., et al.,	
	31	September 26, 2008 Amendment to the Memorandum and Order on Plaintiff's concurrent litigation captioned Amg Pharmaceuticals, Inc., et al., U.S. District of Delaware, CA No. 06-259	motion, in en, Inc. et District Co	the al. v. Ariad	
	32	October 3, 2008 Memorandum Order Greenying in Part of Defendant's Moti Judgment Pursuant to Fed. R. Civ. P concurrent litigation captioned Amg Ariad Pharmaceuticals, Inc., et al. for the District of Delaware, CA No	on to Dismis . 54(b), in en, Inc., et , U.S. Distr	s or for the <i>al.</i> v. ict Court	
	22	October 3, 2008 Judgment in Favor o the concurrent litigation captioned Ariad Pharmaceuticals, Inc., et al. for the District of Delaware, CA No	Amgen, Inc., U.S. Distr	, et al. v. ict Court	
EXAMINEI SIGNATUR		DATE CONSIDERED			

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark here if English language Translation is attached.

Form P	[O-1	449 Substitute	U.S. Departme	ent of Commerce	Application Number	10/037 <u>,3</u> 41	
			Patent and Tra	ademark Office	Filing Date	January 4, 20	002
					First Named Inventor	David Baltimo	re
INFORM	мат	ION DISCLOSI	TRE STATEME	'NT	Art Unit	1636	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)					Examiner Name	D. Guzo	
						75723-	
					Attorney Docket No.	ZA/JPW/GJG/CS	s
					·	<u></u>	
			NON PATENT	LITERATURE DOC	UMENTS		0.4
Examiner Initials*	Cite No. ¹		rnal, serial, symposiu	L LETTERS), title of the m, catalog, etc.) date, pa d/or country where publ	ge(s), volume-issue nu		T ²
	31	the concurre Ariad Pharma	ent litigati a <i>ceuticals,</i>	of Appeal to on captioned Inc., et al. aware, CA No	Amgen, Inc., , U.S. Distr	, et al. v. ict Court	
						~ 1	

				,	42.00		
EXAMINE		•	-	DATE CONSIDERED			

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark here if English language Translation is attached.